Diabetic foot ulcers

An algorithm for assessment and dressing selection

S Car Sullar

al a

Contraction of the second



Holistic foot ulcer managem

Assessment of patients and their feet

Medical history

• Physical, physiological and psychosocial health

Feet inspection

- Callus, cracks
- Colour, erythema
- Temperature
- Dry skin
- Eczema

2

• Oedema of feet/lower legs

3 Neuropathy

- Motor neuropathy (deformities)
- Sensory neuropathy (loss of sensation and vibration. Tests with 10g Monofilament or Ipswich Touch Test and tuning fork)
- Autonomic neuropathy (dry skin, cracking skin, callus)

Vascular status and oxygenation levels

- Palpation of peripheral pulses: femoral, popliteal and pedal (dorsalis pedis and posterior tibial) pulses
- Doppler assessment and ABPI
- Toe-brachial index (TBI)
- Potential referral to a specialist for a full vascular assessment
- Consider oxygen assessment e.g. with transcutaneous oximetry (TcPO₂)

Wound and periwound

Infection:

Local signs of infection can be: increased exudate, nonhealing, malodour, friable or discoloured granulation tissue, redness, pain, heat and swelling. If osteomyelitis is suspected, or an active spreading infection, refer to a multidisciplinary footcare team immediately.

Wound bed, status/colour:

- Black necrotic tissue
- Yellow slough
- Red granulation tissue, pink epithelialisation

Depth

Exudate

- Amount (none, low, moderate, high)
- Consistency/colour
- Wound location
- Wound size (area/depth)
- Wound edge (raised edge, undermining/tracks/ sinuses)
- Surrounding skin (maceration/excoriation, erythema, oedema)
- Exposed bones, tendons, joint capsules or orthopaedic implants
- Pain (location, frequency, cause, type, intensity and duration)
- **Odour** (presence and nature)

Classification

e.g. Wlfl, University of Texas, Wagner, PEDIS or SINBAD



4

Goals of treatment, education and concordance with the patient

6

60-second Diabetic Foot Screen a Screening tool (2018).¹

Management of DFU²

A patient with a diabetic foot ulcer (DFU) or at risk of developing a DFU needs to be referral to a multidisciplinary footcare team (MDFT). They can provide with e.g.

- Offloading wound and risk areas with specialist foot wear.
- Full vascular assessment
- Oedema treatment.
- Infection control and treatment.
- Wound debridement/cleansing and treatment recommendation.
- Nutritional advice.
- Optimal diabetes control.

Remember:

- Assess and manage pain (local and systemic) before dressing changes.
- Be aware of the arterial blood supply. If dry black necrosis - keep dry and refer for a full vascular assessment.
- Moisturize lower extremities and feet daily. Do not put lotion between toes.
- Educate on self-treatment for healthy feet.

For complete and updated assessment and management guidance please visit International Working Group on the Diabetic Foot (IWGDF) www.iwgdfguidelines.org

Be aware of systemic infection symptoms:

- Fever
- Hypotension
 - Rigour Chills
- Multi-organ
- failure
- Read more at: www.mdcalc.com/sirs-sepsis-septicshock-criteria


These recommendations are aligned with the International best practice guidelines: IWGDF practical guidelines on the prevention and management of diabetic foot disease, 2019.

- Previous amputations • Gangrene
- Inspecting nails and between the toes

• Deformities e.g. Charcot

foot (need for x-ray/MRI)

ent in patients with diabetes





For infected DFUs (see picture), aggressive debridement, topical antiseptics and systemic antibiotics are generally recommended. Active spreading infection must be referred as a matter of urgency to a MDFT. Topical antimicrobial agents, e.g. in cleansers or dressings, may be used in combination with antibiotics to treat mild infections. Such dressings or cleansers may also be used alone to treat DFUs which are highly at risk of developing infections.^{2,6}

I

- Optimal wound management with provision of local treatment need to be supported with appropriate management of systemic disease, pressure offloading and debridement. Remember that surgical debridement is contraindicated if ischaemia is present⁴
- Monitor at each dressing change and reassess regularly. Be sure that the dressing is compatible with shoes and other offloading therapies and can be accommodated without bulk and creasing
- If you need to cut the dressing, consider using nonbordered products
- For fixation, consider using Tubifast®
- If you need to dress a toe, consider using Mepitel[®] One or Mepilex[®] Lite for good conformability
- The choice of dressings must be based on local protocols
 and clinical judgement

Proven choice for a better outcome

Safetac[®] is the original less-pain contact layer with silicone adhesion. We designed it to mould softly to skin without sticking to the moist wound⁷ – so you can remove it easily without damaging the skin⁸. That means less pain for your patients⁹.

Safetac also protects new tissue and intact skin – so wounds remain undisturbed to support faster natural healing¹⁰⁻¹³. And it seals the wound margins to protect skin from damaging leaks and maceration^{14,15}. This combination of less pain⁹ and less skin damage^{8,11-14,16} – to support faster healing¹⁰⁻¹³ – can also reduce the cost of treatment^{11,12,16}.

SafetaC

CHNOLOGY

You can trust Mölnlycke® dressings with Safetac, for better patient and economic outcomes.



Skin stripping occurs with traditional adhesive⁶



No skin stripping occurs with Safetac technology⁸

lälplusko[®] drassing calestian quiv

Dressing information



Please note: This guide is not comprehensive and the reader should always refer to local guidelines. References: 1. NLDWs 40-second Diabetic Foel Screen. Screening tool. Canadian Association of Wound Care: Nuvex.cnc. et 2011. https://guidelines.diabetes.ca/docs/resources/Inlows-60-screen-Wounds-Canada.pdf. 2018. 2. World Linio of Wound Heating Societies. World World Screent Appropriate use of topical hearopoints in chronic wounds. PL 40. Appropriate use of topical hearopoints in chronic wound margement: Consensus recommendations. Wound & XD15;WMA Species: 39-05. 6. Indivice, N. Mc 2016. J. Available al: http://www.ound.area.pdf. 2018. 2. Nuvex. A. L. Heathyling and treating foot users in patients with diabetes: saving leet, legs and lines. J. Wound Care 2018;27 (Suppl 5): 51-52. 5. Chavdick, P. J. Awailable al: http://www.ound.shrenational.eum Accessed 8 November 27: 81. 37. Nuite R. Evidence for atraumatics of silicone wound ressing use. Wounds UK 2006;14:10: 40-109. 8. Wounds, K. Zubez, M. E. Reference, Structure, M. R. Scheden, R. P. Humbach, D. J. Weitzer, H. E. Reference, Comparative, J. Wound Care 2011;20: 41-22. N. Mile, R. A. Huntiantonal assure of the assessment of leaving theraming wound the saming and the comparative and the approximation. Wound Structure, Marka 2. U. D. Subrit, M. K. Watez, H. L. Brein, N. et al. An evaluation of the saming and theraming of the assessment of the assessment of the approximation of the sing of the saming and the sing of the assessment of the sing of the assessment of the sing of the s



Mölnlycke Health Care AB, Box 13080, Gamlestadsvägen 3C, SE-402 52 Göteborg, Sweden. Phone +46 31 722 30 00. The Mölnlycke, Mepilex, Mextra, Tubifast, Exufiber, Mepitel, TwoWay Stretch, Granulox and Safetac trademarks, names and logotypes are registered globally to one or more of the Mölnlycke Health Care group of companies. © 2019 Mölnlycke Health Care AB. All rights reserved. HQIM001114